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Abstract Purpose: The aim of
this in vitro study was to evaluate
potential determinants of drug loss in
different ECMO circuits. Meth-
ods: Midazolam, morphine,
fentanyl, paracetamol, cefazolin, me-
ropenem and vancomycin were
injected into three neonatal roller
pump, two paediatric roller pump and
two clinically used neonatal roller
pump circuits, all with a silicone
membrane, and two neonatal centrif-
ugal pump circuits with
polypropylene hollow-fibre mem-
branes. Serial blood samples were
taken from a post-oxygenator site.
Drug recovery was calculated as the
ratio between the determined and the
theoretical maximum concentration.
The latter was obtained by dividing
dose by theoretical circuit volume.
Results: Average drug recoveries at
180 min in three neonatal silicone
membrane roller pump circuits were
midazolam 0.62%, morphine 23.9%,
fentanyl 0.35%, paracetamol 34.0%,
cefazolin 84.3%, meropenem 82.9%
and vancomycin 67.8%. There was a
significant correlation between the
lipophilicity of the drug expressed as
log P and the extent of drug absorp-
tion, p \ 0.001. The recovery of
midazolam and fentanyl in centrifugal
pump circuits with hollow-fibre
membrane oxygenator was signifi-
cantly higher compared to neonatal
roller pump circuits with silicone
membranes: midazolam 63.4 versus
0.62%, fentanyl 33.8 versus 0.35%,
p \ 0.001. Oxygenator size and used
circuits do not significantly affect
drug losses. Conclusions: Signifi-
cant absorption of drugs occurs in the
ECMO circuit, correlating with
increased lipophilicity of the drug.
Centrifugal pump circuits with hol-
low-fibre membrane oxygenators
show less absorption for all drugs,
most pronounced for lipophilic drugs.
These results suggest that pharmaco-
kinetics and hence optimal doses of
these drugs may be altered during
ECMO.
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Abbreviations
CPB Cardiopulmonary bypass
CFZ Cefazolin
ECMO Extracorporeal membrane
oxygenation
FEN Fentanyl
HPLC High-performance
liquid chromatography
ICU Intensive care unit
LQD Limits of quantification
MDZ Midazolam
MEM Meropenem
MOR Morphine
PAR Paracetamol
UPLC-
MS/MS
Ultra-performance
liquid chromatography
with tandem mass
spectrometry detection
VAN Vancomycin
Introduction
Extracorporeal membrane oxygenation (ECMO) is a form
of prolonged temporary cardiopulmonary bypass for car-
diac and/or respiratory failure unresponsive to other
treatment. In general, patients on ECMO receive more
than 10 drugs during ECMO for sedation, analgesia and
treatment of underlying or concomitant conditions [1].
Altered pharmacokinetics of several drugs such as mor-
phine, midazolam, vancomycin and gentamicin have been
observed during ECMO; the volume of distribution is
generally increased, whereas clearance is decreased [2–5].
Evidence-based dosing regimes on ECMO are sparse,
with only a few clinical–pharmacological trials [6].
Absorption of medication in ECMO circuits appears to be
one of the reasons for the increased volume of distribu-
tion. The studies on this subject have left important
questions unanswered [7–11]. Levels of drug absorption
by polymers, silicone rubber and other materials have
been linked to the drugs’ lipophilicity. Assuming this
holds for ECMO membranes and tubing as well, there
might be a correlation between drug loss and lipophilicity,
expressed as log P (or the partition coefficient between
1-octanol and water). Other system-related factors
affecting drug loss include the type of pump and circuit,
reduced absorption by hollow-fibre membranes, shorter
tubing and circuits with a centrifugal pump or roller pump
systems. As the total absorptive capacity is linked to the
total surface area, paediatric systems, with their larger
membrane oxygenators and longer tubing, are expected to
show larger absorption, although this has yet to be
established in trial settings. Finally, if absorption is
maximized by saturation of the surface, one would expect
clinically used ECMO circuits to show less absorption
than freshly blood-primed ECMO circuits, but reports are
contradictory [9, 11].
Aiming at evaluating these aspects, we set out to test
drug loss in different ECMO circuits. The drugs studied
are some of the most frequently used sedatives (midazo-
lam), analgesics (fentanyl, morphine, paracetamol) and
antibiotics (vancomycin, meropenem, cefazolin) in
ECMO patients treated in the two ICUs participating in
this study. To assess the effect of lipophilicity on
absorption these drugs were also chosen to reflect a wide
range of log P values.
Materials and methods
The study was conducted at the ICU of the Sophia Chil-
dren’s Hospital, Erasmus MC, Rotterdam, the
Netherlands, and the neonatal intensive care unit, Uni-
versity Hospitals Leuven, Belgium. The same
investigators conducted the experiments at both sites.
Three different ECMO circuits were compared (Table 1).
Contrary to the Leuven ECMO circuits, the standard setup
of the ECMO circuit in the Sophia Children’s Hospital,
Erasmus MC, Rotterdam, includes a hemofilter.
ECMO circuits
New ECMO circuits were primed according to hospital-
based protocols. The only exception was the age of
erythrocytes used for priming: Leftover erythrocytes over
1 week old were used. ECMO circuits were primed with
carbon dioxide, Ringer’s lactate solution, albumin,
tris(hydroxymethyl)aminomethane, sodium bicarbonate
and erythrocytes. Drug losses in three freshly primed
neonatal roller pump circuits were used as reference
values for comparison with two freshly primed neonatal
centrifugal circuits, two freshly primed paediatric circuits,
and two used neonatal circuits. Used circuits were tested
within 6 h after decannulation, without replacement of
their contents. Medication prior to decannulation con-
sisted of continuous midazolam (150–200 lg/kg/h) and
morphine (15–25 lg/kg/h) infusions for more than 12 h,
cefotaxime (50 mg/kg twice daily) and amoxicillin
(50 mg/kg three times daily), magnesium sulphate
(50 mg/kg four times daily), hydrocortisone (1 mg/kg
three times daily) and vancomycin (15 mg/kg). Temper-
ature, hematocrit and pH values were maintained within
normal ranges.
ECMO circuits were made continuous via an incor-
porated bridge connection. As the centrifugal circuits
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lacked a bridge connection, these circuits were made
continuous with the use of a reservoir bag containing
50 mL of priming fluid. The ECMO circuit was filled to
maximal capacity with pre-oxygenator pressures of
250 mmHg. Before injection of the drugs an equal vol-
ume of fluid was subtracted from the ECMO circuit. The
volume of the neonatal roller pump circuit was estimated
at 350 mL, that of the paediatric circuit volume at
900 mL and that of the centrifugal circuit volume
(including reservoir) at 200 mL. Flow rates were set at
350 mL/min for neonatal circuits and 1,000 mL/min for
paediatric circuits.
Drug administration
Drugs were injected at 5-s intervals into a pre-bladder
injection site simulating actual drug administration in
patients. The line was flushed with at least 3 mL of
physiological saline solution (0.9%) in between injection
of the different drugs to avoid crystallization or depot
effects. Drugs were dosed according to a standardized
weight for a newborn (3 kg) and for an older child
(15 kg). The order of drug injection was the following
(neonatal/paediatric): fentanyl 15 lg/75 lg, morphine
0.6 mg/3 mg, midazolam 0.6 mg/3 mg, paracetamol
45 mg/250 mg, cefazolin 150 mg/750 mg, meropenem
60 mg/300 mg, vancomycin 30 mg/250 mg.
Samples
Samples were taken from a post-oxygenator line before
injection and 2, 4, 6, 8, 10, 30, 60 and 180 min after
injection. Whole blood was collected in polypropylene
tubes containing ethylenediaminetetraacetate (EDTA) and
chilled to 4C until further processing. The blood samples
were centrifuged (6 min at 3,0009g) after which the
plasma supernatant was transferred to polypropylene
cryogenic vials with polyethylene screw caps (Nalgene
Labware, Rochester, NY, USA). Samples were stored at
-80C until analysis. Absence of drug absorption by
pipettes used to transfer samples (PVC, glass and poly-
propylene) was confirmed by testing the recovery of
fentanyl morphine and midazolam from an aqueous
standard after having been in a pipette tip for 3 min.
Quantification of analytes in plasma
Drugs were quantified via ultra-performance liquid
chromatography with tandem mass spectrometry detec-
tion (UPLC-MS/MS) (Waters Corp., Milford, MA, USA).
Antibiotics and analgesics/sedatives were quantified
via two similar methods.
See the method published by Ahsman et al. [12]. The
limits of quantification (LOQ) were 0.2 ng/mL (CFZ,
MEM), 0.7 ng/mL (VAN), 0.5 ng/mL (fentanyl), 5 ng/mL
(midazolam), 2.5 ng/mL (morphine) and 1 lg/mL
(paracetamol).
Ratio of whole blood/plasma concentrations
Theoretical maximum concentration in blood was calcu-
lated by dividing the administered dose by the volume of the
ECMO circuit. However, since drug assays were performed
in plasma, the ratio between the plasma and the blood
Table 1 Description of tested circuits
Description Neonatal roller pump Neonatal centrifugal pump Paediatric roller pump Neonatal (used) roller pump
Priming
volume
(ml)
350 200 900 350
Tubing Medtronic Sh. 70 USP class
VI 1/4 9 1/16 superTygon
Intercept CLASS VI
1/4 9 1/16
Medtronic Sh. 70 USP
class VI 3/8 9 3/32
superTygon
Medtronic Sh. 70 USP
class VI 1/4 9 1/16
superTygon
Oxygenator Medtronic 1.5 m2 silicone
membrane, Paediatric
Extended Capacity
Membrane Oxygenator
MEDOS HILITE 800LT
RHEOPARIN coated
polypropylene microporous
hollow-fibre
Medtronic I-2500-2A
2.5 m2 silicone
Surgical Membrane
Oxygenator
Medtronic 1.5 m2 silicone
membrane, Paediatric
Extended Capacity
Membrane Oxygenator
Heat
exchanger
Medtronic Heat Exchanger
Monitoring adapter and
Luer-lock
NA Medtronic Heat
Exchanger
Monitoring adapter
and Luer-lock
Medtronic Heat Exchanger
Monitoring adapter and
Luer-lock
Hemofilter Hospal Multiflow 100 NA Hospal Multiflow 100 Hospal Multiflow 100
Remarks Freshly primed, reference
group
Freshly primed Freshly primed Clinically used for at least 48 h
before experiment
Manufacturers: Medtronic, Minneapolis, USA; Medos Medizintechnik AG, Stolberg, Germany; Hospal, Lyon, France
NA not applicable
2111
concentration had to be determined to calculate drug
recovery. The blood plasma ratio was calculated as the
average of the concentration in spiked whole blood samples
divided by spiked plasma samples. This was done in tripli-
cate; the mean value was used to calculate whole blood
concentrations from measured plasma concentrations.
Data analysis
Data were plotted and analysed with Graphpad Prism
v4.03 (Graphpad Software Inc., La Jolla, CA, USA). In
the used circuits, pre-existing drug levels (as assessed
from the samples taken at 0 min) were subtracted from
subsequent measurements. Concentrations were con-
verted from plasma to the corresponding whole blood
concentrations using the blood plasma ratio. To calculate
the percentage of drug recovered from the circuit, the
drug concentration 180 min after infusion was divided by
the theoretical concentration, as calculated from the
administered amount of drug divided by the estimated
circuit volume. The log P values for the individual drugs
are derived from the University of Alberta Drugbank
website [13]. A Student’s t test (p \ 0.05) was used to
assess statistical significance of a difference in recoveries
in neonatal versus paediatric and used versus new circuits.
A non-linear sigmoidal curve fit was applied to plot the
recovery versus log P, based on theoretical binding
kinetics. Correlation between log P values and recovery
rates was calculated by using a two-sided Spearman test.
Results
Ratio of whole blood/plasma
The average ratios of whole blood/plasma for each drug
were 1.41 (meropenem), 1.23 (vancomycin), 1.21 (cefaz-
olin), 0.94 (morphine), 0.90 (paracetamol), 0.77 (fentanyl)
and 0.75 (midazolam). There was no discernible trend in
ratio versus incubation time. The relative standard devia-
tion over all whole blood samples was 10% or less.
Drug loss
Table 2 lists the average recoveries after 180 min and
range for each category.
Neonatal roller pump circuits
In the three neonatal roller pump circuits, fentanyl,
midazolam, morphine and paracetamol showed signifi-
cant reduced drug recovery within the first 2 min
(Fig. 1a). While morphine and paracetamol reached an
apparent steady state within 10 min, midazolam and
fentanyl did not: a decrease in recovery appeared to
continue for at least 120 min. Drug recoveries after
2 min for fentanyl, midazolam, morphine and paraceta-
mol were 1.3, 7.5, 27 and 40.7%, respectively. After
180 min, drug recovery decreased to 0.4, 0.6, 24 and
34.1%, respectively.
Antibiotic recovery was much higher (Fig. 1b). After
2 min, 87% of cefazolin, 82% of meropenem and 75%
of vancomycin were recovered in the plasma samples.
After 180 min, an apparent steady state had been
reached at 85, 83 and 68% of the expected concentra-
tion, respectively. For most drugs, especially the
lipophilic drugs (midazolam, morphine), a large fraction
of the administered dose appears to have been lost
within 2 min of circulation. Despite having been injected
first, fentanyl starts to appear only after 4 min, indicat-
ing strong pooling or absorption in the early phase of the
experiment.
Correlation between recovery and log P
Since there were no statistically significant differences in
recovery between all of the roller pump circuits, these
systems were all combined (n = 8) to assess the corre-
lation between recovery and lipophilicity. A sigmoidal
curve best described the data, without apparent patterns in
residuals versus log P values (Fig. 2). There was a sig-
nificant correlation between log P and recovery (df = 53,
rspearman = 0.807, p \ 0.001).
Table 2 Recovery in % (range) of drugs after 180 min of circulation
System Neonatal roller
pump (n = 3)
Neonatal centrifugal
pump (n = 2)
Paediatric roller
pump (n = 2)
Neonatal (used)
roller pump (n = 2)
MDZ 0.62 (0.47 to 0.73) 63.4 (61.6 to 65.2)* 0.74 (0.66 to 0.81) -0.06 (-0.93 to 0.81)
MOR 23.9 (14.6 to 35.8) 32.1 (31.9 to 32.3) 30.5 (28.6 to 32.4) 29.8 (17.1 to 42.6)
FEN 0.35 (0.15 to 0.50) 33.8 (32.4 to 35.3)* 0.28 (0.18 to 0.37) 0.54 (0.36 to 0.72)
PAR 34.0 (29.4 to 41.8) 44.2 (40.8 to 47.6) 44.9 (44.3 to 45.4) 47.3 (42.4 to 52.3)
CFZ 84.3 (72.4 to 100.8) 97.9 (92.5 to 103.3) 49.4 (44.7 to 54.1) 76.7 (65.7 to 87.6)
MEM 82.9 (69.1 to 101.4) 89.1 (76.4 to 101.7) 58.1 (54.4 to 61.9) 72.9 (60.1 to 85.7)
VAN 67.8 (49.2 to 95.3) 67.1 (61.6 to 72.6) 54.4 (43.4 to 65.3) 53.8 (47.4 to 60.3)
* Statistically significant deviation (group averages, two-tailed, p \ 0.001) from new neonatal system with roller pump
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Centrifugal versus roller pump circuits
There was a significant difference in drug recovery
between the roller pump and centrifugal pump circuits for
midazolam (0.6 vs. 63%, p \ 0.001) and fentanyl (0.4 vs.
34%, p \ 0.001). Morphine recovery appeared higher in
the centrifugal circuits, but without statistical significance
(24.0 vs. 32.2%, p = 0.38). Drug recovery was compa-
rable in both circuits for paracetamol, vancomycin,
meropenem and cefazolin after 180 min.
Paediatric versus neonatal circuits
Sedatives and analgesics losses were similar in neonatal
and paediatric circuits at 180 min. Meropenem and
cefazolin losses in the paediatric circuits were higher than
those in neonatal circuits, but without statistical signifi-
cance (Table 2).
Used versus new circuits
The average pre-existing concentrations in the used cir-
cuits were midazolam 344 ng/mL, morphine 16 ng/mL,
fentanyl less than 0.5 ng/mL, paracetamol less than 1 lg/
mL, cefazolin less than 0.2 ng/mL, meropenem less than
0.2 ng/mL, vancomycin 10.5 ng/mL.
Midazolam loss in the first 10 min in used circuits was
lower than that in new ECMO circuits: 4.1 versus 26.1%,
p = 0.0004. This difference had disappeared after
180 min (Table 1). There were no other significant dif-
ferences in drug loss between used and freshly primed
neonatal roller pump circuits.
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Fig. 1 Average recovery versus time for a analgesics and seda-
tives, b antibiotics. Neonatal roller pump circuits (9), neonatal
centrifugal pump circuits (filled circles), paediatric roller pump
circuits (filled diamonds) and neonatal used roller pump circuits
(open squares)
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Discussion
This comprehensive in vitro study enabled us to answer
several questions regarding absorption of drugs in ECMO
circuits. First of all, drug loss is correlated to the indi-
vidual drugs’ log P values and absorption might therefore
be predicted from a drug’s log P value. More lipophilic
drugs such as fentanyl and midazolam disappeared almost
completely, whereas the less lipophilic antibiotics showed
much lower loss (10–35%).
Secondly, midazolam and fentanyl recoveries were
significantly higher in the centrifugal ECMO circuits. For
lipophilic drugs, circuit size and/or type of oxygenator
seems to influence absorption. Others reported a marked
difference in drug loss between polypropylene micropo-
rous or tubular membranes and silicone-based CPB
membranes [14]. Our study was not designed to localize
the site of drug loss and therefore only general conclu-
sions may be drawn. Less PVC tubing, different
oxygenators and inclusion of a hemofilter may all con-
tribute to the differences found. Because of technical
difficulties, temperatures of the centrifugal circuits were
maintained at 29C and not at 35–37C. This discrepancy
may have contributed to the differences found. On the
other hand, Skacel et al. [15] showed no clear differences
in drug losses between circuits maintained at low tem-
peratures (24–25C) and normal temperatures (37C).
Thirdly, we found no significant difference between
our paediatric and neonatal roller pump circuits; perhaps
the effects of an increased dose and the increased polymer
surface, combined with a relatively larger circulating
volume, cancel each other out. If there is a saturation
effect of binding sites, an increased initial dose or number
of binding sites may increase or decrease the level of drug
recovery. Although single dose studies show significant
adsorption it is unclear what effect multiple doses will
have on this process.
Finally, contrary to previous reports [9, 11], we found
no significant difference in drug loss between freshly
primed and used ECMO circuits after 180 min.
In the present study concentrations of most drugs
declined within the first minutes of ECMO after which an
apparent steady state was reached. This was not the case for
midazolam and fentanyl; concentrations of these drugs
declined continuously during the 3-h period. This suggests
the presence of a greater amount of binding sites for
midazolam and fentanyl than for the other compounds. As
alternative explanations, the loading dose used is below the
saturation threshold or steady state is reached after 3 h. This
might explain the findings for the freshly primed circuits,
but does not explain why similar absorption patterns were
found in the used ECMO circuits. An alternative explana-
tion—degradation by enzymes or other causes—is unlikely
since both drugs are exclusively metabolized in the liver. In
vitro experiments simulating continuous infusions or
multiple dosing may help to clarify this issue.
Increased absorption could be a cause of the increased
dose requirements seen for midazolam [16]. The increase,
however, does not equal the greater than 90% loss of
midazolam observed; apparently other factors affect drug
absorption in the in vivo setting. Fentanyl shows the
lowest recovery and takes a long time to appear at the
other end of the circuit, which suggests pooling or a
strong tendency to bind to any available binding site. This
phenomenon has major clinical implications: as fentanyl
and other lipophilic drugs will not be as effective when
administered at a pre-oxygenator line they should be
given directly to the patient instead to minimize drug loss.
Morphine is absorbed to a lower extent, and is therefore
the preferred opioid for ECMO patients.
Midazolam, fentanyl, morphine and vancomycin los-
ses in the roller pump circuits were higher than those
previously reported [7, 8, 11, 17]. Several factors may
perhaps explain this discrepancy. Most studies are based
on one to three ECMO circuits and we found substantial
variability between individual circuits. There are several
potential causes of these differences. A different t = 0
composition of the circulating contents might have
affected adsorption, which could suggest varying degrees
of protein binding or drug displacement by concomitantly
present compounds. The degree of use (or ‘wear and
tear’) of the circuits could affect drug adsorption. There is
also some potential for inaccuracy in the injection of
drugs into the circuit due to pooling of drugs in the
pressure monitor bladder (especially for those drugs in a
highly concentrated solution), which could cause vari-
ability in adsorption in new and used circuits alike.
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Finally, there could have been some sampling- or assay-
related variability (although unlikely to be this large, and
it is also unlikely that this effect would be consistently
visible over all sampling times).
The variability makes it difficult to compare the results
from different studies. Mehta et al. reported stable fentanyl
concentrations in blood-primed circuits for up to 3 h,
although in their wet primed circuit fentanyl loss at 3 h was
78% [8]. After 24 h fentanyl was no longer detectable
indicating ongoing drug loss in the ECMO circuit, similar
to our observations for midazolam and fentanyl. Both
studies tested roller pump circuits with a Medtronic sili-
cone membrane, but experimental methods were distinctly
different. Mehta et al. used a reservoir bag pre-primed with
medication before connecting this to the ECMO circuit;
altered distribution within the ECMO circuit or reservoir
bag could result in different time-dependent elimination
curves. Another potential cause of variation is the presence
of a hemofilter in the ECMO circuit, which we now use
routinely to manage the fluid balance and improve caloric
intake [18–20]. There was no dialysate flow during the in
vitro trial but drug loss by the hemofilter membrane might
have occurred. We tested several drugs simultaneously to
simulate actual medication administration in ECMO
patients. Although we cannot completely rule out drug–
drug interactions, we consider this experimental approach
to accurately reflect daily clinical practice.
The goal of this in vitro study was to evaluate potential
determinants of drug loss in different ECMO circuits. In
this study we tried to mimic the clinical situation in which
solutions of routinely used drugs are injected into blood-
primed circuits at short intervals. Previous studies were
done in aqueous media, [7, 17] or a spiked bag of blood to
represent a patient [8]. The use of a whole blood system
with assays in plasma required us to determine a ratio of
whole blood concentration and plasma concentration and
the estimation of the total volume, but the resulting
experimental setup is close to the clinical situation.
Without the use of a reservoir, baseline concentrations
could not be measured. Instead, theoretical concentrations
were estimated from dose and estimated volume of the
ECMO circuits. This may have led to over- or underes-
timation of percentage drug losses. Priming volumes of
all three circuits are known, however, and any error in
estimated volume should not exceed 5%, and equally
affects all drugs. The general trend therefore is clear:
sedatives and analgesics are lost due to absorption by
membranes or tubing, whereas antibiotics are affected to a
much lesser extent. This confirms observations done in
studies of cardiopulmonary bypass circuits [10, 21, 22].
Conclusions
Significant uptake of drugs occurs in the ECMO circuit,
which could lead to unexpectedly low initial plasma
concentrations and higher loading dose requirements for
lipophilic drugs in particular. The log P value may be
used to predict drug loss for roller pump circuits. Appli-
cation of centrifugal pump circuits with hollow-fibre
membrane oxygenators limits absorption for all drugs,
notably lipophilic drugs. Oxygenator size and previous
use of a circuit do not significantly affect drug losses. In
combination with the interpatient variability that is
inherent to critically ill children, these drug losses likely
contribute to the altered pharmacokinetics observed in
patients on ECMO.
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